
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is confident in the success of their Phase 2 combo trial for eloralintide and tirzepatide in overweight and obese patients with T2D, projected to have risk-adjusted sales of $13.6B in 2032, driven by pent-up demand for a new weight-loss monotherapy and promising combination potential. The combination of eloralintide and tirzepatide in a single injection could also offer a better efficacy and tolerability ratio compared to tirzepatide monotherapy. Additionally, Eli Lilly's focus on neuroscience, cardiometabolic, cancer, and immunology with key products such as Verzenio, Jardiance, Taltz, and Olumiant, positions the company for continued growth despite competition and potential regulatory threats in the PBM market.
Bears say
Eli Lilly is a well-established drug firm with a diverse portfolio of products targeting major medical areas such as cancer, cardiometabolic diseases, and immunology. However, with recent concerns over the potential of adverse effects in clinical trials and the company's reliance on a few key products, there is a negative outlook for the stock. Additionally, the company's earnings and financials may be impacted by ongoing challenges in the retail and pharmacy reimbursement sectors, potentially leading to slower revenue growth and profitability.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares